Want to see CMPX full AI Analyst Report?
CMPX Stock Chart & Stats
$6.00
$0.48(33.57%)
At close: 4:00 PM EST
$6.00
$0.48(33.57%)
Day’s Range― - ―
52-Week Range$1.61 - $6.88
Previous CloseN/A
Volume16.21M
Average Volume (3M)4.13M
Market Cap
$412.40M
Enterprise Value$238.11M
Total Cash (Recent Filing)$194.69M
Total Debt (Recent Filing)$9.79M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding180,087,920
10 Day Avg. Volume4,107,482
30 Day Avg. Volume4,129,840
Financial Highlights & Ratios
PEG Ratio-0.76
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-322.64
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$9.38Price Target Upside56.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.44
Revenue Forecast (FY)-$2.22M
Bulls Say, Bears Say
Bulls Say
Strong Phase 2/3 Efficacy For TovecimigCOMPANION-002 demonstrated statistically significant PFS and higher ORR for tovecimig plus paclitaxel versus paclitaxel alone in a 168-patient second-line biliary tract cancer study. Durable efficacy and tolerability create a substantive clinical basis for regulatory discussions and commercial planning.
Antibody Discovery And Engineering PlatformCompass’s core competency is antibody discovery and engineering, enabling multiple monoclonal antibody and combination programs. A platform-driven R&D model supports repeatable candidate generation, pipeline breadth, and potential collaborations that sustain long-term program value.
Relatively Solid Balance Sheet And Runway VisibilityThe balance sheet shows low leverage (debt-to-equity ~0.05) and meaningful equity (~$186.5M TTM). This financial positioning, coupled with management’s stated runway planning, provides a multi-quarter buffer to advance registrational activities and commercialization preparations without immediate refinancing pressure.
Bears Say
Pre-revenue With Sizable, Worsening LossesCompass remains pre-revenue with substantial, persistent losses (TTM net income -$68.2M) and negative free cash flow (-$53.3M). Operating cash outflows have worsened over time, reducing internal funding capacity and making the company reliant on external capital to sustain operations and trial/commercial timelines.
High Financing And Dilution RiskAs a clinical-stage biotech with no recurring product revenues, Compass depends on external financing (equity, collaborations, milestones). Given the expanding cash burn and negative earnings, the company faces ongoing financing and dilution risk, which constrains strategic flexibility and shareholder value over the medium term.
Regulatory/approval Risk From OS Outcome And CrossoverAlthough PFS and ORR were positive, overall survival lacked statistical significance in the intent-to-treat population because 54% of control patients crossed over to tovecimig. This outcome introduces interpretive and regulatory complexity that can lengthen approval timelines or require additional evidence to satisfy regulators.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics, Inc.’s price range in the past 12 months?
Compass Therapeutics, Inc. lowest stock price was $1.61 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics, Inc.’s market cap?
Compass Therapeutics, Inc.’s market cap is $412.40M.
When is Compass Therapeutics, Inc.’s upcoming earnings report date?
Compass Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 28 days.
How were Compass Therapeutics, Inc.’s earnings last quarter?
Compass Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.002.
Is Compass Therapeutics, Inc. overvalued?
According to Wall Street analysts Compass Therapeutics, Inc.’s price is currently Undervalued.
Does Compass Therapeutics, Inc. pay dividends?
Compass Therapeutics, Inc. does not currently pay dividends.
What is Compass Therapeutics, Inc.’s EPS estimate?
Compass Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Compass Therapeutics, Inc. have?
Compass Therapeutics, Inc. has 180,087,920 shares outstanding.
What happened to Compass Therapeutics, Inc.’s price movement after its last earnings report?
Compass Therapeutics, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went up 0.515%.
Which hedge fund is a major shareholder of Compass Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.38 (56.25% Upside)
$9.38 (56.25% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.62%
12-Months-Change
Fundamentals
Return on Equity
-39.75%
Trailing 12-Months
Asset Growth
56.08%
Trailing 12-Months
Company Description
Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$9.38
▲(56.25% Upside)
Technical Analysis
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
12.74% Insiders
7.09% Mutual Funds
67.57% Other Institutional Investors
0.36% Public Companies and
Individual Investors